Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Rat (Rattus) MAP3K7 Antibodies:
anti-Human MAP3K7 Antibodies:
anti-Mouse (Murine) MAP3K7 Antibodies:
Go to our pre-filtered search.
Human Polyclonal MAP3K7 Primary Antibody for DB - ABIN389721
Huang, Chiang, Hung, Hou: Targeting of TGF-β-activated protein kinase 1 inhibits chemokine (C-C motif) receptor 7 expression, tumor growth and metastasis in breast cancer. in Oncotarget 2015
overexpression of miR (show MLXIP Antibodies)-20a reduced colony formation and tumor growth. Furthermore, the data revealed that the function of miR (show MLXIP Antibodies)-20a was probably exerted via targeting the TAK1 expression. Overexpression of miR (show MLXIP Antibodies)-20a sensitizes the osteosarcoma cells to chemotherapeutic drugs.
TGFbeta (show TGFB1 Antibodies) and IL1beta (show IL1B Antibodies) signaling interact at the SMAD2 (show SMAD2 Antibodies)/3 level in human primary MSC (show MSC Antibodies). Down-stream TGFbeta (show TGFB1 Antibodies) target genes were repressed by IL1beta (show IL1B Antibodies) independent of C-terminal SMAD2 (show SMAD2 Antibodies) phosphorylation. We demonstrate that SMAD2 (show SMAD2 Antibodies)/3 linker modifications are required for this interplay and identified TAK1 as a crucial mediator of IL1beta (show IL1B Antibodies)-induced TGFbeta (show TGFB1 Antibodies) signal modulation.
increased TAK1 expression may be involved in the progression of gastric cancer.
miR (show MLXIP Antibodies)-146a, serving as a tumor suppressor, may significantly promote GC cell apoptosis by inhibition of the NF-kappaB (show NFKB1 Antibodies) signaling pathway via targeting TAK1.
In conclusion, for the first time, we report that TRADD (show TRADD Antibodies), TRAF2 (show TRAF2 Antibodies), RIP1 (show UQCRFS1 Antibodies) and TAK1 play a role in the regulating TNF-alpha (show TNF Antibodies) signalling in human myometrium. These findings are of significance given the central role of TNF-alpha (show TNF Antibodies) in the processes of human labour and delivery.
Rab1 (show RAB1A Antibodies) is regulated by the host in a similar fashion, and that the innate immunity kinase TAK1 and Legionella effectors compete to regulate Rab1 (show RAB1A Antibodies) by switch II modifications during infection.
nMet accelerated HCC (show FAM126A Antibodies) tumorigenesis and metastasis via the activation of TAK1/NF-kappaB (show NFKB1 Antibodies) pathway.
TAK1 protein expression increased in cartilage tissue from spinal tuberculosis patients.
TAK1 regulates Nrf2 (show GABPA Antibodies) through modulation of Keap-p62/SQSTM1 (show SQSTM1 Antibodies) interaction. This regulation is important for homeostatic antioxidant protection in the intestinal epithelium.
Overexpression of TAK1 was strongly associated with positive lymph node metastasis in pancreatic ductal adenocarcinoma.
TAK1 (show NR2C2 Antibodies) inhibits HBV primarily at viral transcription level through activation of MAPK (show MAPK1 Antibodies)-JNK (show MAPK8 Antibodies) pathway.
we generated the transgenic mouse line with deletion of Tak1 and gain of function of Bmpr1a. This compound mutation leads to more severe craniofacial deformities than each single mutation.
Data indicate TNF receptor associated factor 6 (TRAF6 (show TRAF6 Antibodies)) as an essential molecular switch leading to cardiac hypertrophy in a transforming growth factor beta-activated kinase 1 (TAK1), -dependent manner.
It is a key regulator of the toll (show TLR4 Antibodies)-like receptor signaling pathway.
The conversion of Tak1 (show NR2C2 Antibodies)-B to Tak1 (show NR2C2 Antibodies)-A consistently led to significant accumulation of lipids in cultured AML12cells, as well as the dysregulation of several lipid metabolism-related genes in mouse liver. Different functional properties of the two isoforms may explain the conflicting functions previously reported for Tak1 (show NR2C2 Antibodies).
demonstrate the efficiency of ad--siRNA-TAK1 (show NR2C2 Antibodies) in controlling joint inflammation of Collagen-Induced Arthritis, which is associated with the suppression of the expression of pro-inflammatory cytokines and JNK (show MAPK8 Antibodies) activation.
These data, in addition to the fact that Map3k7 is upregulated in the sinus venous-the source of cells for the SAN-suggest that Map3k7 may be an endogenous regulator of the SAN fate
These results present a novel in vivo function, the negative role of TAK1 (show NR2C2 Antibodies) in marginal zone B-cell development that is likely associated with NF-kappaB2 activation.
Tnfr1 (show TNFRSF1A Antibodies) deletion partially restored thymic and lung macrophages.
TAK1 (show NR2C2 Antibodies) is required for PPARgamma (show PPARG Antibodies) transactivation and promotes PPARgamma (show PPARG Antibodies) transcriptional activity synergistically with TAK1 binding protein 1 (TAB1 (show TAB1 Antibodies)).
The protein encoded by this gene is a member of the serine/threonine protein kinase family. This kinase mediates the signaling transduction induced by TGF beta and morphogenetic protein (BMP), and controls a variety of cell functions including transcription regulation and apoptosis. In response to IL-1, this protein forms a kinase complex including TRAF6, MAP3K7P1/TAB1 and MAP3K7P2/TAB2\; this complex is required for the activation of nuclear factor kappa B. This kinase can also activate MAPK8/JNK, MAP2K4/MKK4, and thus plays a role in the cell response to environmental stresses. Four alternatively spliced transcript variants encoding distinct isoforms have been reported.
mitogen-activated protein kinase kinase kinase 7
, TGF-beta-activated kinase TAK1
, TGF-beta activated kinase 1
, TGF-beta-activated kinase 1
, transforming growth factor-beta-activated kinase 1
, mitogen activated protein kinase kinase kinase 7
, transforming growth factor beta-activated kinase 1